Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Declopramide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.64 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.58 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.58 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.58 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.58 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.58 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.58 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.58 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.58 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.58 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.58 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.58 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.58 |
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.58 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.58 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.58 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.54 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.50 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Declopramide SCHEMBL922516 | 0.99 | LMNA (0.66) | LMNABLMPMP22ALDH1A1SLC22A1 | |
| Declopramide SCHEMBL30719968 | 0.99 | LMNA (0.66) | LMNABLMPMP22ALDH1A1SLC22A1 | |
| Declopramide SCHEMBL5925509 | 0.95 | ALDH1A1 (0.61) | LMNABLMPMP22ALDH1A1SLC22A1 | |
| SCHEMBL2956109 | 0.86 | ALDH1A1 (0.71) | LMNABLMPMP22ALDH1A1SLC22A1 | |
| SCHEMBL18768840 | 0.86 | HPGD (0.63) | LMNABLMPMP22ALDH1A1SLC22A1 | |
| SCHEMBL3435195 | 0.85 | LMNA (0.52) | LMNABLMPMP22ALDH1A1SLC22A1 | |
| SCHEMBL12886918 | 0.84 | ALDH1A1 (0.68) | LMNABLMPMP22ALDH1A1SLC22A1 | |
| SCHEMBL5924476 | 0.84 | ALDH1A1 (0.68) | LMNABLMPMP22ALDH1A1SLC22A1 | |
| SCHEMBL10079549 | 0.83 | SMN1; SMN2 (0.56) | LMNAALDH1A1TSHRCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL23702334 | 0.81 | BLM (0.65) | LMNABLMPMP22ALDH1A1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0927030-A4 | USE OF ARYL N-SUBSTITUTED CARBOXAMIDES TO KILL TUMORS | OXIGENE INC (US) | 2000-01-26 | — | — | EP | claimed |
| EP-0927030-A1 | USE OF ARYL N-SUBSTITUTED CARBOXAMIDES TO KILL TUMORS | OXIGENE, INC. (US) | 1999-07-07 | — | — | EP | claimed |
| WO-1997032576-A1 | USE OF ARYL N-SUBSTITUTED CARBOXAMIDES TO KILL TUMORS | OXIGENE, INC. (US) | 1997-09-12 | — | — | WO | claimed |
| EP-1009402-B1 | COMPOSITIONS AND USE OF BENZAMIDES AS ANTI-INFLAMMATORY AGENTS | OXIGENE INC (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-0927030-B1 | USE OF ARYL N-SUBSTITUTED CARBOXAMIDES TO KILL TUMORS | OXIGENE INC (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6713517-B1 | USING N-(2-DIETHYLAMINO-ETHYL)-4-AMINO-3-CHLOROBENZAMIDE | OXIGENE, INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1009402-A1 | COMPOSITIONS AND USE OF BENZAMIDES AND NICOTINAMIDES AS ANTI-INFLAMMATORY AGENTS | OXIGENE, INC. (US) | 2000-06-21 | — | — | EP | disclosed |
| EP-1009402-A4 | COMPOSITIONS AND USE OF BENZAMIDES AND NICOTINAMIDES AS ANTI-INFLAMMATORY AGENTS | OXIGENE INC (US) | 2000-06-21 | — | — | EP | disclosed |
| US-6028111-A | Compositions and use of benzamides and nicotinamides as anti-inflammatory agents | OXIGENE, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0927030-A4 | USE OF ARYL N-SUBSTITUTED CARBOXAMIDES TO KILL TUMORS | OXIGENE INC (US) | 2000-01-26 | — | — | EP | disclosed |
| EP-0927030-A1 | USE OF ARYL N-SUBSTITUTED CARBOXAMIDES TO KILL TUMORS | OXIGENE, INC. (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1997032582-A1 | COMPOSITIONS AND USE OF BENZAMIDES AND NICOTINAMIDES AS ANTI-INFLAMMATORY AGENTS | OXIGENE, INC. (US) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997032576-A1 | USE OF ARYL N-SUBSTITUTED CARBOXAMIDES TO KILL TUMORS | OXIGENE, INC. (US) | 1997-09-12 | — | — | WO | disclosed |